Evidence map›Paper›PMID 32617646›Full record

Trial reportPsychopharmacology2020

The catechol-O-methyltransferase inhibitor tolcapone modulates alcohol consumption and impulsive choice in alcohol use disorder.

Allison R Coker, Dawn N Weinstein, Taylor A Vega, Catriona S Miller, Andrew S Kayser, Jennifer M Mitchell

Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Psychopharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02740582 (Effects of Tolcapone on Decision Making and Alcohol Intake Using a Laboratory Bar in Moderate to Heavy Social Drinkers), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02740582 phase2completednot on this map

Effects of Tolcapone on Decision Making and Alcohol Intake Using a Laboratory Bar in Moderate to Heavy Social Drinkers

TypeinterventionalSponsorJennifer MitchellRan2016 to 2019Enrolled62ConditionsAlcohol Abuse, Impulsive BehaviorArmsTolcapone, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Cortical dopamine reduces the impact of motivational biases governing automated behaviour.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Trial
  2. Review
  3. Article
  4. Cyclic Nucleotide Phosphodiesterases in Alcohol Use Disorders: Involving Gut Microbiota.The international journal of neuropsychopharmacology · 2023
    Article
  5. Article
  6. Association ofGenes · 2021
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Allison R CokerDepartment of Neurology, University of California, San Francisco, CA, USA. allison.coker@ucsf.edu.
Dawn N WeinsteinDepartment of Neurology, University of California, San Francisco, CA, USA.
Taylor A VegaDepartment of Neurology, University of California, San Francisco, CA, USA.
Catriona S MillerDepartment of Neurology, University of California, San Francisco, CA, USA.
Andrew S KayserDepartment of Neurology, University of California, San Francisco, CA, USA.
Jennifer M MitchellDepartment of Neurology, University of California, San Francisco, CA, USA.
University of California, San Francisco · USVA Northern California Health Care System · US

Funding

Dopaminergic Mechanisms Underlying Human Social Behavior: A Multimodal ApproachR01MH112775 · NIMH · UNIVERSITY OF CALIFORNIA BERKELEY · PI HSU, MING, KAYSER, ANDREW S · 2019 to 2023
$3.5M
Behavioral and Neural Correlates of Social Function in Alcohol Use DisordersR01AA026587 · NIAAA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAYSER, ANDREW S · 2018 to 2022
$2.3M
NIAAA NIH HHS R01 AA026587NIMH NIH HHS R01 MH112775U.S. Department of Defense W81XWH-12-2-0048U.S. Department of Defense W81XWH-13-2-0075
6 · The paper itself

Abstract

rationaleIndividuals suffering from alcohol use disorder (AUD) demonstrate difficulty with decision-making and impulsivity that may be associated with impaired frontal cortical function. Therapeutics that enhance frontal dopamine tone could decrease impulsivity and in turn reduce alcohol consumption in individuals with AUD.

objectivesTo determine if the catechol-O-methyltransferase (COMT) inhibitor tolcapone can attenuate alcohol consumption in individuals with AUD and whether this attenuation correlates with tolcapone-induced changes in laboratory-based decision-making tasks.

methodsWe used daily self-report and a novel group laboratory bar task to assess the effects of randomized double-blind crossover administration of tolcapone (100 mg TID for 5 days) on alcohol consumption and laboratory tasks assessing impulsivity in 55 non-treatment-seeking subjects with AUD.

resultsTolcapone significantly reduced self-reported alcohol consumption (t (54) = 2.05, p = 0.045). The effects of tolcapone on drinking significantly correlated with changes in impulsive decision-making, such that subjects with the greatest decrease in impulsive choice on tolcapone also reported the greatest decrease in alcohol consumption (r (45) = 0.40, p = 0.0053). We did not see effects of tolcapone on laboratory bar consumption. Adverse event (AE) reporting was low, with no significant difference in frequency or severity of AEs on tolcapone versus placebo.

conclusionsThese data demonstrate that COMT inhibitors such as tolcapone may be useful therapeutics for AUD.

trial registrationClinicalTrials.gov Identifier: NCT02740582.

Indexed as

AdultAlcohol DrinkingAlcoholismCatechol O-Methyltransferase InhibitorsChoice BehaviorCross-Over StudiesDouble-Blind MethodFemaleHumansImpulsive BehaviorMaleTolcaponeYoung AdultCatechol O-Methyltransferase InhibitorsTolcaponeAlcohol use disorderAUDCOMTDecision-makingImpulsivityTolcapone

Identifiers

PMID32617646
PMCPMC7529919
OpenAlexW3039460773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.